Compare · BDX vs SGHT
BDX vs SGHT
Side-by-side comparison of Becton Dickinson and Company (BDX) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $58.96B, about 100.2x SGHT ($588.6M).
- BDX has been more active in the news (11 items in the past 4 weeks vs 5 for SGHT).
- BDX has more recent analyst coverage (25 ratings vs 21 for SGHT).
- Company
- Becton Dickinson and Company
- Sight Sciences Inc.
- Price
- -
- -
- Market cap
- $58.96B
- $588.6M
- 1M return
- +13.16%
- -
- 1Y return
- +43.79%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 21
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest BDX
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
- BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
- BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Latest SGHT
- Sight Sciences to Present at Two Upcoming Investor Conferences
- Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
- Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- H.C. Wainwright initiated coverage on Sight Sciences with a new price target
- EVP, Operations & R&D Taylor Brenton sold $26,453 worth of shares (2,988 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Bauerlein Alison sold $223,627 worth of shares (25,260 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rodberg James sold $63,812 worth of shares (7,208 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)